Zimmer Biomet has recently received FDA 510(k) clearance for its Rosa robotic-assisted total shoulder replacement system, marking a significant advancement in the field of orthopedic surgery. The system, designed for use in anatomic or reverse total shoulder replacement techniques, is the latest addition to the company’s Rosa robotics portfolio, which already includes the Rosa total knee replacement and Rosa total hip replacement systems.

The announcement was made in a press release by Zimmer Biomet Holdings Inc., with Ivan Tornos, the president and CEO of the company, expressing pride and excitement in being the first to deliver a robotic surgical assistant for anatomic and reverse shoulder replacement surgery. Tornos emphasized the novel advancement of the Rosa shoulder system, intended to enable surgeons to leverage the power of robotics and data analytics for highly complex shoulder procedures with accuracy and efficiency.

According to the press release, the Rosa shoulder system is set to be commercially available in the U.S. in the second half of 2024, offering a promising solution for orthopedic surgeons and patients alike.